A detailed history of Geode Capital Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 5,166,204 shares of EXEL stock, worth $148 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,166,204
Previous 5,241,765 1.44%
Holding current value
$148 Million
Previous $124 Million 6.68%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$20.34 - $23.73 $1.54 Million - $1.79 Million
-75,561 Reduced 1.44%
5,166,204 $116 Million
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $1.95 Million - $2.31 Million
96,447 Added 1.87%
5,241,765 $124 Million
Q4 2023

Feb 13, 2024

BUY
$19.25 - $24.13 $1.36 Million - $1.7 Million
70,573 Added 1.39%
5,145,318 $123 Million
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $785,247 - $937,843
41,242 Added 0.82%
5,074,745 $111 Million
Q2 2023

Aug 11, 2023

BUY
$18.17 - $20.48 $4.82 Million - $5.44 Million
265,404 Added 5.57%
5,033,503 $96.2 Million
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $3.29 Million - $3.92 Million
201,810 Added 4.42%
4,768,099 $92.5 Million
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $3.42 Million - $3.98 Million
228,943 Added 5.28%
4,566,289 $73.2 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $1.17 Million - $1.66 Million
74,758 Added 1.75%
4,337,346 $68 Million
Q2 2022

Aug 12, 2022

SELL
$17.44 - $23.16 $193,706 - $257,238
-11,107 Reduced 0.26%
4,262,588 $88.7 Million
Q1 2022

May 13, 2022

BUY
$17.03 - $22.67 $2.67 Million - $3.56 Million
156,861 Added 3.81%
4,273,695 $96.9 Million
Q4 2021

Feb 11, 2022

BUY
$15.84 - $21.88 $1.74 Million - $2.4 Million
109,609 Added 2.74%
4,116,834 $75.3 Million
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $553,955 - $718,442
33,985 Added 0.86%
4,007,225 $84.7 Million
Q2 2021

Aug 13, 2021

BUY
$17.95 - $25.56 $917,460 - $1.31 Million
51,112 Added 1.3%
3,973,240 $72.4 Million
Q1 2021

May 12, 2021

BUY
$20.53 - $25.22 $2.08 Million - $2.55 Million
101,180 Added 2.65%
3,922,128 $88.6 Million
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $4.35 Million - $5.86 Million
236,344 Added 6.59%
3,820,948 $76.7 Million
Q3 2020

Nov 13, 2020

SELL
$20.67 - $26.94 $2.47 Million - $3.21 Million
-119,327 Reduced 3.22%
3,584,604 $87.6 Million
Q2 2020

Aug 13, 2020

BUY
$16.46 - $27.42 $1.4 Million - $2.33 Million
84,837 Added 2.34%
3,703,931 $87.9 Million
Q1 2020

May 14, 2020

BUY
$14.46 - $21.8 $1.98 Million - $2.99 Million
137,125 Added 3.94%
3,619,094 $62.3 Million
Q4 2019

Feb 13, 2020

BUY
$15.15 - $18.89 $1.6 Million - $2 Million
105,861 Added 3.14%
3,481,969 $61.4 Million
Q3 2019

Nov 12, 2019

BUY
$17.68 - $22.65 $724,031 - $927,562
40,952 Added 1.23%
3,376,108 $59.7 Million
Q2 2019

Aug 14, 2019

BUY
$18.93 - $24.75 $3.44 Million - $4.49 Million
181,560 Added 5.76%
3,335,156 $71.3 Million
Q1 2019

May 14, 2019

BUY
$19.6 - $24.76 $2.83 Million - $3.57 Million
144,142 Added 4.79%
3,153,596 $75.1 Million
Q4 2018

Feb 13, 2019

BUY
$13.65 - $21.8 $2.87 Million - $4.58 Million
210,181 Added 7.51%
3,009,454 $59.2 Million
Q3 2018

Nov 13, 2018

BUY
$15.87 - $22.4 $2.82 Million - $3.98 Million
177,653 Added 6.78%
2,799,273 $49.6 Million
Q2 2018

Aug 14, 2018

BUY
$18.56 - $22.45 $2.16 Million - $2.61 Million
116,110 Added 4.63%
2,621,620 $56.4 Million
Q1 2018

May 15, 2018

BUY
$22.15 - $31.89 $1.41 Million - $2.03 Million
63,668 Added 2.61%
2,505,510 $55.5 Million
Q4 2017

Feb 13, 2018

SELL
$24.23 - $30.93 $409,220 - $522,376
-16,889 Reduced 0.69%
2,441,842 $74.2 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $8.08 Million - $10.1 Million
346,184 Added 16.39%
2,458,731 $59.6 Million
Q2 2017

Aug 14, 2017

BUY
N/A
2,112,547
2,112,547 $52 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $9.25B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.